Age, sex, and secondary prevention of ischaemic heart disease in everyday practice

Jankowski, Piotr; Czarnecka, Danuta; Wolfshaut–Wolak, Renata; Łysek, Radosław; Łukaszewska, Anna; Surowiec, Sławomir; Loster, Magdalena; Bogacki, Piotr; Bryniarska-Mirek, Ewa; Grodecki, Janusz; Nessler, Jadwiga; Podolec, Piotr; Kawecka‐Jaszcz, Kalina; Pająk, Andrzej

doi:10.5603/kp.a2013.0148

Cited by 9 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studied groups and the methods used in the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease have been described in earlier reports [10][11][12]. A brief description is given below.…”

Section: Methodsmentioning

confidence: 99%

Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, aging is related to a higher probability of having high blood pressure, diabetes mellitus and hypercholesterolemia and of being inactive, as well as other modifiable risk factors. 20 Overall, hypertension and diabetes mellitus are 2 of the most important risk factors for ischemic heart disease in people of all ages and is the major risk factor in the elderly. 4,[21][22][23] In Spain and Andalusia, the prevalence of both hypertension and diabetes mellitus increased with age.…”

Section: Age Effectmentioning

confidence: 99%

Age, Period, and Cohort Effects on Mortality From Ischemic Heart Disease in Southern Spain

Ocaña-Riola

Mayoral-Cortés

Fernández-Ajuria

et al. 2015

Revista Española de Cardiología (English Edition)

View full text Add to dashboard Cite

“…Age is one of the primary risk factors for CVD and is associated with worst likelihood values in modifiable risk factors and risk of mortality. 28 Otherwise, variability in the follow-up is considered an essential indicator of quality. 29 We did not observe a relationship between the length of follow-up and the outcomes observed, except for two subgroup analyses which included studies involving elderly individuals and patients with a history of heart failure or kidney disease.…”

Section: Introductionmentioning

confidence: 99%

Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo examine the relationship between glycated haemoglobin A1c (HbA1c) levels and the risk of cardiovascular outcomes and all-cause mortality based on data from observational studies and to determine the optimal levels of HbA1c for preventing cardiovascular events and/or mortality in diabetic and non-diabetic populations.Review methodsWe systematically searched Medline, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews and Web of Science databases, from inception to July 2016, for observational studies addressing the association of HbA1c levels with mortality and cardiovascular outcomes. Random effects models were used to compute pooled estimates of HR and respective 95% CI for all-cause mortality, cardiovascular mortality and risk of cardiovascular events, separately for people with and without diabetes.ResultsSeventy-four published studies were included in the systematic review, but only 46 studies could be incorporated in the meta-analysis. In both diabetic and non-diabetic populations, there was an increase in the risk of all-cause mortality when HbA1c levels were over 8.0% and 6.0%, respectively. The highest all-cause mortality in people with diabetes was HbA1c above 9.0% (HR=1.69; 95% CI 1.09 to 2.66) and in those without diabetes was HbA1c above 6.0% (HR=1.74; 95% CI 1.38 to 2.20). However, both diabetic and non-diabetic populations with lower HbA1c levels (below 6.0% HR=1.57; 95% CI 1.14 to 2.17 and below 5.0% HR=1.19; 95% CI 1.04 to 1.36, respectively) had higher all-cause mortality. Similar pooled estimates were found when cardiovascular mortality was the outcome variable.ConclusionHbA1c is a reliable risk factor of all-cause and cardiovascular mortality in both diabetics and non-diabetics. Our findings establish optimal HbA1c levels, for the lowest all-cause and cardiovascular mortality, ranging from 6.0% to 8.0% in people with diabetes and from 5.0% to 6.0% in those without diabetes.

show abstract

Age, sex, and secondary prevention of ischaemic heart disease in everyday practice

Abstract: We found no major sex-related difference in the frequency of achieving recommended goals in secondary prevention, whereas age was related to a lower prevalence of smoking and a higher probability of having high blood pressure in subjects after hospitalisation for coronary artery disease.

Cited by 9 publications

References 29 publications

Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?

Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?

Age, Period, and Cohort Effects on Mortality From Ischemic Heart Disease in Southern Spain

Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis

Contact Info

Product

Resources

About